Promotes Parkinson's Disease Via Modulating Pathway

taurine upregulated gene 1 () participates in nervous system diseases, but its function in Parkinson's disease (PD) remains unclear. This study explored the function and mechanism of in PD. A PD model was constructed using SH-SY5Y cells induced by 1-methyl-4-phenylpyridinium (MPP) and mice treated by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) . The expressions of , , phosphatase and tensin homologue (), tyrosine hydroxylase (TH), and Bcl-2, and cleaved caspase-3 expressions were determined by quantitative reverse transcription-PCR and Western blotting. The viability, apoptosis, reactive oxygen species, and release of inflammatory factors from SH-SY5Y cells and substantia nigra tissues were detected by commercial kits. The interaction between and was analyzed by dual-luciferase reporter assay. Hematoxylin/eosin and immunohistochemical staining was performed for assessing the pathological damage and proportion of TH-positive cells. In PD cell model and mice model, expression was upregulated and that of was downregulated. Further research showed that sponged and regulated expression. Silencing of not only protected SH-SY5Y cells against cell apoptosis, oxidative stress, and neuroinflammation , pathological damage and neuroinflammation , but also suppressed the expressions of and cleaved caspase-3, and increased the expressions of TH and Bcl-2 in MPP-treated SH-SY5Y cells. However, the protective role of siTUG1 in SH-SY5Y cells was significantly inhibited by the inhibitor. Thus, knocking down might have a protective effect on PD through the pathway.